Cullinan Therapeutics (CGEM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cullinan Therapeutics (CGEM) is Neutral.

The composite score behind that read is -0.03, weighing +0.07 of bullish evidence against -0.31 bearish.

Cullinan Therapeutics last closed at $15.53, +0.45% on the session.

Against the IVW growth benchmark the position is -0.35% over the forecast window.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

8 graded predictions for CGEM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cullinan Therapeutics in the 17th percentile on return on equity, where 100 is best.

Cullinan Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $994.93M.

StockMap tracks Cullinan Therapeutics as the 132nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Cullinan Therapeutics ranks 126th of 381 in the group, against a group median of -0.08.